-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation.
Wright A, Wright D, Syngelaki A, Georgantis A, Nicolaides KH.
Am J Obstet Gynecol 2019;220:197.e1-197.e11. pdf -
Two-stage approach for prediction of small-for-gestational-age neonate and adverse perinatal outcome by routine ultrasound examination at 35-37 weeks' gestation.
Akolekar R, Panaitescu AM, Ciobanu A, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:484-491. pdf -
The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D'Alton M, Berghella V, Nicolaides KH, Hod M.
Int J Gynaecol Obstet 2019;Suppl 1:1-33. pdf -
Predictive performance of the competing risk model in screening for preeclampsia.
Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH.
Am J Obstet Gynecol 2019;220:199.e1-199.e13. pdf -
Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
Ciobanu A, Rouvali A, Syngelaki A, Akolekar R, Nicolaides KH.
Am J Obstet Gynecol 2019;220:486.e1-486.e11. pdf -
Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A, Wright A, Panaitescu A, Syngelaki A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2019;220:584.e1-584.e11. pdf -
Prediction of adverse perinatal outcome by serum placental growth factor and soluble fms-like tyrosine kinase-1 in women undergoing induction of labor.
Fiolna M, Machuca M, Karampitsakos T, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:604-608. pdf -
PlGF isoform 3 in maternal serum and placental tissue.
Frang H, Hurskainen P, Nicolaides K, Sairanen M.
Pregnancy Hypertens 2019;18:9-13. pdf -
Impaired placental perfusion and major fetal cardiac defects.
Fantasia I, Andrade W, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;53:68-72. pdf -
Good clinical practice advice: First trimester screening and prevention of pre-eclampsia in singleton pregnancy.
FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine.
Int J Gynaecol Obstet 2019;144:325-329. pdf -
First-trimester metabolomic prediction of stillbirth.
Bahado-Singh RO, Syngelaki A, Mandal R, Han B, Li L, Bjorndahl TC, Wang N, Maulik D, Dong E, Turkoglu O, Tseng CL, Zeb A, Redman M, Wishart DS, Nicolaides KH.
J Matern Fetal Neonatal Med 2019;32:3435-3441. pdf -
Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A, Jabak S, De Castro H, Frei L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:79-86. pdf -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum S100 protein in normal and Down syndrome pregnancies.
Abraha HD, Noble PL, Nicolaides KH, Sherwood RA.
Prenat Diagn 1999;19:334-6.